Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurochem has received recommendations from both the North American and European Data Safety Monitoring Boards to continue its two ongoing phase III clinical trials for Alzhemed in Alzheimer's disease.
Subscribe to our email newsletter
In North America, this fifth recommendation by the monitoring board was based on the recent review of the available safety data from 1,052 patients who have been on study medication for an average of 12.9 months.
In Europe, this first recommendation by monitoring board members was based on their recent review of the available safety data from 333 patients who have been on study medication for an average of 1.8 months.
Alzhemed is a small, orally-administered molecule known as an amyloid (B) antagonist. Alzhemed (tramiprosate) crosses the blood-brain-barrier, binds to soluble A(B) peptide and interferes with the amyloid cascade that is associated with amyloid deposition and the toxic effects of A(B) peptide in the brain.
Current treatments for Alzheimer’s disease provide benefit to patients through the alleviation of symptoms; however, the underlying disease is not directly affected. Research is now capitalizing on advanced knowledge about the biochemistry of A(B) and the pathway by which it is produced.